eXoZymes appoints Damien Perriman as CCO to lead commercial growth

EXOZYMES INC.

Damien Perriman appointed to newly created CCO role, effective April 2, 2025.
Perriman brings 20+ years experience commercializing biotechnologies; previously at Genomatica (Geno) and Gevo.
Focus on commercial opportunities, spin-outs, joint ventures, and licensing deals with future partners.
CEO Michael Heltzen: hire reflects strategic focus on scaling and commercializing biosolutions across multiple sectors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.